MS@thelimits 2018

M
Do you want to attend the MS@thelimits 2018 meeting?  This year the focus is on cellular therapies, comorbidities and trials in more advanced MS. 


Have a look at the programme. 



Following on the success of last year’s MS at the limits meeting in London we are holding a second meeting this November. 


The feedback we got from last year’s meeting was exceptionally good and I think it was due to the quality of the speakers and the format; i.e. 20-minute talk and 20-minute discussion. 


If you want to attend please register online.



ProfG    








About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.

5 comments

  • Treatment cessation?

    Background: Several disease-modifying drugs (DMD) are available for the treatment of MS, and most patients with relapsing-remitting disease are currently treated. Data on when and how DMD treatment can be safely discontinued are scarce. Methods: Fifteen MS patients, treated with natalizumab for >5 years without clinical and radiological signs of inflammatory disease activity, suspended treatment and were monitored with MRI examinations and clinical follow-up to determine recurrence of disease activity. This group was compared with a retrospectively analysed cohort comprising 55 MS patients treated with first-line DMDs discontinuing therapy in the time period of 1998-2015 after an analogous stable course. Results: Natalizumab discontinuers were followed for on average 19 months, and follow-up data for 56 months were available for first-line DMD quitters. Two-thirds of natalizumab treated patients experienced recurrent inflammatory disease activity, and one third had recurrence of rebound character. In contrast, 35% of first-line DMD quitters had mild recurrent disease activity, and no one exhibited rebound. Conclusions: Withdrawal of a first-line DMD after prolonged treatment in middle-aged MS patients with stable disease appears to be relatively safe, while natalizumab withdrawal in a similar group of patients cannot be safely done without starting alternative therapy.

    Discontinuation of disease modifying treatments in middle…. Available from: https://www.researchgate.net/publication/312643608_Discontinuation_of_disease_modifying_treatments_in_middle_aged_multiple_sclerosis_patients_First_line_drugs_vs_natalizumab [accessed Apr 26 2018].

    Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab

    https://www.researchgate.net/publication/312643608_Discontinuation_of_disease_modifying_treatments_in_middle_aged_multiple_sclerosis_patients_First_line_drugs_vs_natalizumab

    Obrigado

  • "Have a look at the programme."

    Love to look at it..unfortunately it is pretty illegible
    due to the low file resolution.
    It's o.k.. you guys are still learning this internet stuff.

  • This sounds great. Can you clarify is this is primarily for researchers/clinicians to get together and work things out, or to inform MSers, or both? As someone with MS I've a vested interest and like to follow the science, but don't want to attend if its a typical conference where specialists talk to each other and let contents fly over the heads of the rest of the audience. Thanks

  • profG may answer, but last time it was full of MS professionals and the debate may fly over your head, sometimes it flies over my head.

By Prof G

Translate

Categories

Recent Posts

Recent Comments

Archives